Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet ...

Market OverviewThe Global RNA Therapeutics Market is valued at USD 13.3 Billion in 2023 and is projected to reach a value ...

Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights ...

Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. The company’s product pipeline comprises ATL1102, an antisense inhibitor ...

Stoke Therapeutics (NASDAQ:STOK – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at Needham & Company LLC in a research note issued on Tuesday,Benzinga reports. They presently ...

Stoke Therapeutics (NASDAQ:STOK – Get Free Report) had its target price raised by analysts at HC Wainwright from $35.00 to $47.00 in a research note issued on Tuesday,Benzinga reports. The firm ...

Biogen Inc. (NASDAQ:BIIB) and Stoke Therapeutics, Inc. (NASDAQ:STOK) collaborated to develop and commercialize zorevunersen ...

Biogen (BIIB) and Stoke Therapeutics (STOK) announced a collaboration for the development and commercialization of zorevunersen, a potential ...

This is the third drug AZ has licensed in as part of strategic collaboration with the antisense therapeutics specialist , which originally began in 2012 in oncology and was later expanded to cover ...